Get more insights on Transthyretin Amyloid Cardiomyopathy Treatment Market
Transthyretin Amyloid Cardiomyopathy Treatment Market is driven by Increasing Prevalence of ATTR-CM Disease
The global transthyretin amyloid cardiomyopathy treatment market is primarily driven by the increasing prevalence of ATTR-CM disease globally. Transthyretin amyloid cardiomyopathy, also known as ATTR-CM, is a rare, progressive, and frequently life-threatening heart disease caused by abnormal deposits of amyloid protein consisting of misfolded transthyretin (TTR) in the heart. ATTR-CM treatment aims to eliminate the pathogenic protein deposits in the heart along with symptomatic management for cardiomyopathy. The currently approved treatment options include tafamidis, inotersen, and diflunisal which are designed to reduce amyloid deposition in tissues and address cardiomyopathy.
The global transthyretin amyloid cardiomyopathy treatment market is estimated to be valued at US$ 1943.69 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period from 2024 to 2031.
The key driver fueling the Transthyretin Amyloid Cardiomyopathy Treatment Market Growth is the rising geriatric population globally that is susceptible to ATTR-CM. Age is a major disease risk factor as the prevalence increases considerably after the age of 60 years. According to United Nations data, the population aged 60 years and above is expected to reach nearly 2.1 billion worldwide by 2050 from 1 billion in 2019. Growing life expectancy along with advanced healthcare has raised the risk of protein misfolding diseases like ATTR-CM emerging as significant public health concerns. Development of new diagnostic methods and biomarkers is also driving earlier disease detection and treatment-seeking rate.
The Asia Pacific region is poised to witness the fastest growth in the global Transthyretin Amyloid Cardiomyopathy Treatment market during the forecast period. This can be attributed to rapidly growing economies, rising healthcare investments, increasing medical insurance coverage, and expansion of healthcare infrastructure in the region. Moreover, growing trade partnerships and collaborations between countries are helping to boost research activities and facilitate technology transfers in the life sciences domain. Countries like China, India, Japan, and South Korea are emerging as global outsourcing hubs and are attracting significant investments for pharmaceutical and biotech facilities. Furthermore, rising awareness about rare diseases, growing geriatric population, and improving access to advanced healthcare are fueling the regional market demand. The governments are also taking initiatives to strengthen regulations to promote innovations. All these factors are expected to drive the Asia Pacific region to the forefront of global Transthyretin Amyloid Cardiomyopathy Treatment market in the upcoming years.
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian